CSL Limited
(ASX:CSL) has obtained US FDA approval for its new influenza vaccine, Flucelvax Qaudrivalent.
The company says that its new vaccine helps protect against two influenza A viruses and two B viruses for the current influenza season, as recommended by the FDA and World Health Organisation.
CSL also says that it has produced the first and only cell culture-derived influenza vaccine in the US that offers four-strain flu protection for people aged 4 years and older.
The medical company also says that its new vaccine will provide healthcare providers and their patients with an important option to broaden their influenza coverage.
CSL reported a net profit of $983.9 million at 31 December 2015.
